Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma. The recommended single-agent dose is 400 mg orally twice a day ...
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14 , 70–76 (2009). Article Google Scholar ...
Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...
A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE ...
Hosted on MSN1mon
Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patientsDawson et al, Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma, JAMA Oncology (2024). DOI: 10.1001/jamaoncol.2024.5403 Provided by NRG Oncology ...
Dana Walker, vice president, Opdivo global programme lead, BMS, said: “HCC is the predominant type of liver cancer globally, including in the EU, and when diagnosed at the advanced or unresectable ...
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback